Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Cash from Investing Activities: 2016-2025

Historic Cash from Investing Activities for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $117.2 million.

  • Ultragenyx Pharmaceutical's Cash from Investing Activities rose 142.53% to $117.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $411.0 million, marking a year-over-year increase of 280.64%. This contributed to the annual value of -$17.8 million for FY2024, which is 110.58% down from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Cash from Investing Activities is $117.2 million, which was up 64.64% from $71.2 million recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Cash from Investing Activities peaked at $119.9 million during Q1 2025, and registered a low of -$275.5 million during Q3 2024.
  • In the last 3 years, Ultragenyx Pharmaceutical's Cash from Investing Activities had a median value of $94.4 million in 2024 and averaged $41.7 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first spiked by 397.91% in 2023, then tumbled by 528.50% in 2024.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Cash from Investing Activities (Quarterly) stood at $69.1 million in 2021, then slumped by 348.49% to -$171.6 million in 2022, then skyrocketed by 37.64% to -$107.0 million in 2023, then surged by 196.00% to $102.7 million in 2024, then skyrocketed by 142.53% to $117.2 million in 2025.
  • Its Cash from Investing Activities was $117.2 million in Q3 2025, compared to $71.2 million in Q2 2025 and $119.9 million in Q1 2025.